TAT-CBD3A6K (acetaat)

TAT-CBD3A6K acetate, is a modified TAT-CBD3 peptide. TAT-CBD3A6K acetate reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K acetate shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function[1][2].

12352209

Calcium Channel

Membrane Transporter/Ion Channel; Neuronal Signaling

Neurological Disease

99.76

O=C([C@@H](N)CC1=CC=C(O)C=C1)NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N2[C@H](C(N[C@H](C(NCC(N[C@H](C(O)=O)CC(C)C)=O)=O)CCCNC(N)=N)=O)CCC2)=O)C(C)C)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCC(O)=O)=O)CCCCN)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)CCCNC(N)=N)=O)C)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCCN)=O)CCCNC(N)=N)=O.CC(O)=O.[x]

C137H250N60O32.xC2H4O2

3249.83 (free base)

[1]Piekarz AD, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012 Jul 24;8:54.|[2]Meloni BP, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther. 2015 Sep;153:36-54.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10358A/TAT-CBD3A6K-acetate-SDS-MedChemExpress.pdf

Peptides

No Development Reported